News

Genethon receives the 2012 Prix Galien France

(read more)

Genethon, member of the Biotherapies Institute for Rare Diseases

The Biotherapies Institute for Rare Diseases, a unique task force to accelerate therapeutic developments, includes 4 laboratories founded and supported by the AFM Telethon : the Institute of Myology, Genethon, I-Stem and Atlantic Gene Therapies (Nantes’ gene therapy research centre). (read more)

Alain Schwenck, an Expert on Pharmaceutical Prodcution, becomes Director of Genethon Bioprod

Alain Schwenck, 51, has joined Genethon as Director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon. (read more)

Fulvio Mavilio, the internationally acknowledged expert in gene therapy for rare diseases, is appointed as Genethon’s new Scientific Director

(read more)

Gene therapy : Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C

(read more)

On the Internet site of the Usine Nouvelle magazine you can discover the Genethon laboratory financed by donations to the Telethon through images from behind the scenes

Both clear and comprehensive, this document will take you to the heart of gene therapy. (read more)

Genethon and Children’s Hospital Boston get FDA approval for a Wiskott Aldrich gene therapy trial

(read more)

Genethon and Wake Forest University School of Medicine (North Carolina) announce their collaboration for a preclinical gene therapy trial

Evry (France), March 8th, 2011 – Genethon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (Association Française contre les Myopathies, AFM) with donations from France’s annual Telethon) and Wake Forest University School of Medicine (Winston Salem, North Carolina, USA) today… (read more)

Partnership for a gene therapy Clinical trial signed between Genethon and Children’s Hospital Boston

(read more)

bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy

(read more)

Thérapie génique – la découverte d’un mini-gène fonctionnel ouvre une nouvelle voie thérapeutique dans les dysferlinopathies

v style=”height:20px” aria-hidden=”true” class=”wp-block-spacer”> (read more)

Innovative biotherapies and genetic eye diseases

(read more)

Généthon initiates a new clinical trial for a severe immune deficiency (Wiskott-Aldrich syndrome)

(read more)

Genethon appoints biopharma industry expert Frédéric Revah as Chief Executive

(read more)

Journée internationale Maladies Rares du 28 février 2010 : Les acteurs de la Plateforme Maladies Rares attendent un second plan français à la hauteur de enjeux

v style=”height:20px” aria-hidden=”true” class=”wp-block-spacer”> (read more)